Revenue GrowthStrong revenue growth indicates increasing demand for BIOTON's products, enhancing its market position and potential for future expansion.

Cash Flow ImprovementImproved cash flow generation enhances BIOTON's ability to reinvest in growth opportunities and maintain financial stability.

Low LeverageA conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.

Bears Say

Declining Profit MarginsDecreasing profit margins indicate challenges in cost management and pricing power, potentially impacting long-term profitability.

Negative Net IncomeNegative net income reflects operational inefficiencies, which can hinder BIOTON's ability to invest in growth and return value to shareholders.

Low Operating Cash FlowLow operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.

7U5 FAQ

What was BIOTON S.A.’s price range in the past 12 months?

BIOTON S.A. lowest stock price was €0.78 and its highest was €1.15 in the past 12 months.

What is BIOTON S.A.’s market cap?

BIOTON S.A.’s market cap is €83.52M.

When is BIOTON S.A.’s upcoming earnings report date?

BIOTON S.A.’s upcoming earnings report date is Mar 27, 2026 which is in 38 days.

How were BIOTON S.A.’s earnings last quarter?

BIOTON S.A. released its earnings results on Oct 30, 2025. The company reported €0.012 earnings per share for the quarter, beating the consensus estimate of N/A by €0.012.

Is BIOTON S.A. overvalued?

According to Wall Street analysts BIOTON S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BIOTON S.A. pay dividends?

BIOTON S.A. does not currently pay dividends.

What is BIOTON S.A.’s EPS estimate?

BIOTON S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BIOTON S.A. have?

BIOTON S.A. has 85,864,200 shares outstanding.

What happened to BIOTON S.A.’s price movement after its last earnings report?

BIOTON S.A. reported an EPS of €0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BIOTON S.A.?

Currently, no hedge funds are holding shares in DE:7U5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BIOTON S.A.

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.